Efficacy and safety of a novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: A phase 3 study - 13/03/20
Abstract |
Background |
FMX101 4% topical minocycline foam has been shown to be an effective and safe treatment for acne vulgaris (AV).
Objective |
To further evaluate the efficacy and safety of FMX101 4% in treating moderate to severe acne vulgaris.
Methods |
A 12-week, multicenter, randomized (1:1), double-blind, vehicle-controlled study was conducted. Coprimary end points were the absolute change in inflammatory lesion count from baseline and the rate of treatment success (Investigator's Global Assessment score of 0 or 1 with a ≥2-grade improvement).
Results |
There were 1488 participants in the intent-to-treat population. The FMX101 4% group had significantly greater reductions in the number of inflammatory lesions from baseline (P < .0001) and a greater rate of treatment success based on Investigator's Global Assessment (P < .0001) versus the foam vehicle group at week 12. FMX101 4% was generally safe and well tolerated.
Limitations |
The efficacy and safety of FMX101 4% were not characterized in participants with mild AV.
Conclusion |
FMX101 4% topical minocycline foam was effective and safe for the treatment of moderate to severe AV.
Le texte complet de cet article est disponible en PDF.Key words : acne vulgaris, clinical study, efficacy, foam, minocycline, randomized, safety, topical administration
Abbreviations used : AV, CI, CK, IGA, LSM, TEAE, AE, ITT
Plan
| Funding sources: Sponsored by Foamix Pharmaceuticals, Inc. |
|
| Disclosure: Drs Raoof, Hooper, Zaiac, Sullivan, Lain, and Moore served as investigators for Foamix Pharmaceuticals. Dr Kircik is an investigator and consultant for Foamix Pharmaceuticals. Dr Jankicevic is a consultant for Foamix Pharmaceuticals. Dr Stuart is an employee and stockholder at Foamix Pharmaceuticals. |
Vol 82 - N° 4
P. 832-837 - avril 2020 Retour au numéro
Article précédent
- Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study
- Hidemi Nakagawa, Osamu Nemoto, Atsuyuki Igarashi, Hidehisa Saeki, Hironobu Kaino, Takeshi Nagata
- DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)
- Vince Bertucci, Nowell Solish, Joely Kaufman-Janette, Steve Yoelin, Ava Shamban, Joel Schlessinger, Daniel Snyder, Conor Gallagher, Yan Liu, Gill Shears, Roman G. Rubio
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?